

Study concept and design:
Heck, Winter.
Acquisition of data:
Thoene, Secci, Winter, Seitz, Nawroth, Tauber,
Thalgott, Schmid, Heck.
Analysis and interpretation of data:
Heck, Winter, Bietenbeck, Seitz.
Drafting of the manuscript:
Heck, Seitz, Winter.
Critical revision of the manuscript for important intellectual content:
Thoene, Bietenbeck, Tauber, Nawroth, Retz, Gschwend, Ruland.
Statistical analysis:
Winter, Heck.
Obtaining funding:
None.
Administrative, technical, or material support:
Ruland.
Supervision:
Heck, Winter.
Other:
None.
Financial disclosures:
Matthias M. Heck certi
fi
es that all con
fl
icts of
interest, including speci
fi
c
fi
nancial interests and relationships and
af
fi
liations relevant to the subject matter or materials discussed in the
manuscript (eg, employment/af
fi
liation, grants or funding, consultan-
cies, honoraria, stock ownership or options, expert testimony, royalties,
or patents
fi
led, received, or pending), are the following: None.
Funding/Support and role of the sponsor:
None.
Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at
http://dx.doi.org/10.1016/ j.eururo.2017.07.024 .References
[1]
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer inci- dence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374 – 403.
[2]
Sridhar SS, Freedland SJ, Gleave ME, et al. Castration-resistant prostate cancer: from new pathophysiology to new treatment. Eur Urol 2014;65:289 – 99.
[3]
Coutinho I, Day TK, Tilley WD, et al. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence. Endocr Relat Cancer 2016;23:T179 – 97.
[4]
de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364: 1995 – 2005.
[5]
Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367: 1187 – 97.
[6]
Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA- 302): fi nal overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015;16:152 – 60.
[7]
Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in meta- static prostate cancer before chemotherapy. N Engl J Med 2014;371:424 – 33.
[8]
Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014;371:1028 – 38.
[9]
Maughan BL, Antonarakis ES. Androgen pathway resistance in prostate cancer and therapeutic implications. Expert Opin Phar- macother 2015;16:1521 – 37.
[10]
Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resis- tance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer 2015;15:701 – 11.[11]
Steinestel J, Luedeke M, Arndt A, et al. Detecting predictive andro- gen receptor modi fi cations in circulating prostate cancer cells. Oncotarget 2015;6:12035 – 47.
[12]
Scher HI, Graf RP, Schreiber NA, et al. Nuclear-speci fi c AR-V7 protein localization is necessary to guide treatment selection in metastatic castration-resistant prostate cancer. Eur Urol 2016;71:874 – 82.[13]
Liu X, Ledet E, Li D, et al. A whole blood assay for AR-V7 and AR v567es in prostate cancer patients. J Urol 2016;196:1758 – 63.
[14]
Todenhöfer T, Azad A, Stewart C, et al. AR-V7 transcripts in whole blood RNA of patients with metastatic castration resistant prostate cancer correlate with response to abiraterone acetate. J Urol 2016;197:135 – 42.[15]
Qu F, Xie W, Nakabayashi M, et al. Association of AR-V7 and prostate-speci fi c antigen RNA levels in blood with ef fi cacy of abir- aterone acetate and enzalutamide treatment in men with prostate cancer. Clin Cancer Res 2017;23:726 – 34.[16]
Del Re M, Biasco E, Crucitta S, et al. The detection of androgen receptor splice variant 7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients. Eur Urol 2017;71:680 – 7.[17]
Usher JL, Athreya K, Ishiba T, et al. Detection of AR-V7 using cell-free RNA (cfRNA) in prostate cancer. J Clin Oncol 2016;34(15 Suppl): 16613.
[18]
Kölbl AC, Jeschke U, Andergassen U. The signi fi cance of epithelial- to-mesenchymal transition for circulating tumor cells. Int J Mol Sci 2016;17:1308.[19]
Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working *Group. J Clin Oncol 2008;26:1148 – 59.[20]
Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205 – 16.[21]
McShane LM, Altman DG, Sauerbrei W, et al. REporting recommen- dations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 2006;100:229 – 35.[22]
Huggett JF, Foy CA, Benes V, et al. The Digital MIQE guidelines: minimum information for publication of quantitative digital PCR experiments. Clin Chem 2013;59:892 – 902.[23]
Takeuchi T, Okuno Y, Hattori-Kato M, et al. Detection of AR-V7 mRNA in whole blood may not predict the effectiveness of novel endocrine drugs for castration-resistant prostate cancer. Res Rep Urol 2016;8:21 – 5.
[24]
Antonarakis ES, Lu C, Luber B, et al. Androgen receptor splice variant 7 and ef fi cacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol 2015;1:582 – 91.[25]
Nakazawa M, Lu C, Chen Y, et al. Serial blood-based analysis of AR- V7 in men with advanced prostate cancer. Ann Oncol 2015;26: 1859 – 65.
[26]
Onstenk W, Sieuwerts AM, Kraan J, et al. Ef fi cacy of cabazitaxel in castration-resistant prostate cancer is independent of the presence of AR-V7 in circulating tumor cells. Eur Urol 2015;68: 939 – 45.
[27]
Bernemann C, Schnoeller TJ, Luedeke M, et al. Expression of AR-V7 in circulating tumour cells does not preclude response to next generation androgen deprivation therapy in patients with castra- tion resistant prostate cancer. Eur Urol 2016;71:1 – 3.[28]
Whale AS, Devonshire AS, Karlin-Neumann G, et al. International interlaboratory digital PCR study demonstrating high reproducibil- ity for the measurement of a rare sequence variant. Anal Chem 2017;89:1724 – 33.
E U R O P E A N U R O L O GY 7 2 ( 2 0 17 ) 8 2 8
–
8 3 4
834